Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Nes Ziona, Israel.
प्रकार | 5 मिनट | 15 मिनट | प्रति घंटा | दैनिक | मासिक |
|---|---|---|---|---|---|
| मूविंग एवरेज | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय |
| तकनीकी संकेतक | मजबूत खरीद | खरीदें | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय |
| सारांश | मजबूत विक्रय | तटस्थ | मजबूत विक्रय | मजबूत विक्रय | मजबूत विक्रय |
नाम | अंतिम | उच्च | निम्न | बदलाव | बदलाव % | वॉल्यूम | समय | ||
|---|---|---|---|---|---|---|---|---|---|
| 375.00 | 384.00 | 361.35 | +0.05 | +0.01% | 42.15K | BSE | |||
| 3.74 | 3.80 | 3.65 | +0.010 | +0.27% | 298.40K | BSE | |||
| 1,141.95 | 1,152.00 | 1,097.85 | +43.30 | +3.94% | 7.28K | BSE | |||
| 1.56 | 1.64 | 1.50 | -0.01 | -0.64% | 85.18K | BSE | |||
| 141.50 | 141.50 | 134.10 | +6.55 | +4.85% | 2.38K | NSE | |||
| 131.00 | 134.15 | 129.70 | +1.85 | +1.43% | 6.79K | NSE | |||
| 10.84 | 11.92 | 10.80 | -0.52 | -4.58% | 908.29K | BSE | |||
| 69.00 | 73.70 | 68.30 | -3.35 | -4.63% | 20.88K | NSE | |||
| 3.30 | 3.50 | 3.20 | -0.05 | -1.49% | 3.40M | NSE | |||
| 935.50 | 1,003.90 | 887.55 | +33.00 | +3.66% | 8.47K | NSE | |||
| 921.05 | 932.00 | 920.00 | -8.15 | -0.88% | 108.51K | NSE | |||
| 13.55 | 13.80 | 13.55 | 0.00 | 0.00% | 0.00 | NSE | |||
| 925.80 | 925.80 | 876.10 | +44.05 | +5.00% | 842.41K | NSE | |||
| 141.00 | 149.45 | 140.50 | -4.50 | -3.09% | 10.69K | NSE | |||
| 0.05 | 0.05 | 0.05 | 0.00 | 0.00% | 0.00 | NSE |